GLP-1 therapies have fundamentally changed employer pharmacy strategy. As manufacturers, digital health companies, and new direct-to-consumer and direct-to-employer models redefine how employees access treatment, employers are facing difficult decisions about affordability, access, member expectations, and fiduciary responsibility. This closing discussion explores how organizations are evaluating emerging care models, responding to growing employee demand, and making strategic decisions that balance access, affordability, and sustainable coverage.